Provided by Tiger Fintech (Singapore) Pte. Ltd.

Axsome Therapeutics

112.21
-0.0300-0.03%
Post-market: 112.210.00000.00%19:35 EDT
Volume:700.76K
Turnover:78.67M
Market Cap:5.52B
PE:-18.72
High:114.01
Open:113.10
Low:111.13
Close:112.24
Loading ...

Axsome Therapeutics Receives FDA Indication in Support of Alzheimer's Drug Submission

MT Newswires Live
·
04 Mar

Axsome Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
03 Mar

Axsome Therapeutics Announces FDA Pre-Nda Meeting Minutes for Axs-05 in Alzheimer’s Disease Agitation Supporting Nda Submission

THOMSON REUTERS
·
03 Mar

Axsome Therapeutics Inc - to Submit Snda for Axs-05 in Q3 2025

THOMSON REUTERS
·
03 Mar

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

GlobeNewswire
·
03 Mar

Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025

Insider Monkey
·
02 Mar

Mizuho Raises Price Target on Axsome Therapeutics to $212 From $195, Maintains Outperform Rating

MT Newswires Live
·
28 Feb

Axsome Therapeutics price target raised to $190 from $125 at Morgan Stanley

TIPRANKS
·
27 Feb

Axsome Therapeutics Inc : Mizuho Raises Target Price to $212 From $195

THOMSON REUTERS
·
27 Feb

Positive Outlook for Axsome Therapeutics Driven by Symbravo’s Promising Study Results and Market Potential

TIPRANKS
·
27 Feb

Axsome Therapeutics Is Maintained at Outperform by Mizuho

Dow Jones
·
27 Feb

Axsome Therapeutics price target raised to $212 from $195 at Mizuho

TIPRANKS
·
26 Feb

Mizuho Securities Adjusts Axsome Therapeutics Price Target to $212 From $195, Maintains Outperform Rating

MT Newswires Live
·
26 Feb

Buy Rating for Axsome Therapeutics Driven by Promising SYMBRAVO Phase 3 Trial Results

TIPRANKS
·
25 Feb

Axsome Therapeutics Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.
·
25 Feb

Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs

Benzinga
·
25 Feb

Axsome Therapeutics’ Symbravo: A Promising Alternative in the Migraine Treatment Market

TIPRANKS
·
25 Feb

BUZZ-U.S. STOCKS ON THE MOVE-BioMarin, Azul, Sun Communities

Reuters
·
24 Feb

BUZZ-U.S. STOCKS ON THE MOVE- Twilio, Bath & Body Works, Wingstop

Reuters
·
24 Feb

Analysts’ Top Healthcare Picks: MiMedx Group (MDXG), Axsome Therapeutics (AXSM)

TIPRANKS
·
24 Feb